Evercore ISI Group Upgrades Guardant Health to Outperform, Raises Price Target to $160

Benzinga Newsdesk www.benzinga.com Positive 94.1%

Neg 0% Neu 0% Pos 94.1%

Evercore ISI Group analyst Vijay Kumar upgrades Guardant Health (NASDAQ:GH) from In-Line to Outperform and raises the price target from $95 to $160.